Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
A Prospective Study of the Efficacy and Safety of Apatinib Monotherapy as First-Line Treatment in Elderly Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Sponsor: The First Affiliated Hospital of Bengbu Medical University
Listed as NCT03219593, this PHASE2 trial focuses on Apatinib and Biomarker and remains ongoing. Sponsored by The First Affiliated Hospital of Bengbu Medical University, it has been updated 8 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
8 versions recorded-
Mar 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Mar 2020 [monthly]
Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- The First Affiliated Hospital of Bengbu Medical University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Bengbu, China